Logotipo do repositório

The Challenges of Antitubercular Drug Discovery

dc.contributor.authorPrates, João Lucas Bruno [UNESP]
dc.contributor.authordos Santos Fernandes, Guilherme Felipe [UNESP]
dc.contributor.authorRodríguez-Silva, Cristhian N.
dc.contributor.authordos Santos, Jean Leandro [UNESP]
dc.contributor.editorNima Rezaei
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUnidad de Posgrado en Farmacia y Bioquímica
dc.date.accessioned2025-04-29T18:37:07Z
dc.date.issued2023-01-01
dc.description.abstractAlthough extensive efforts have been undertaken to eradicate tuberculosis (TB), it remains one of the deadliest infections. The rising number of drug-resistant strainsStraindrug-resistant contributing to high mortalityMortality rates has become a global concern, highlighting the need for suitable treatments to eliminate such strains. However, the limitations of current therapies are long treatment duration, adverse side effectsSide effect, interactions with other drugs, toxicity, and poor efficacyEfficacy against latent strains. Thus, the search for safe and effective anti-TB drugsDruganti-TB is urgent. This chapter addresses the advances and challengesChallenge in drug discoveryDiscoverydrug for treating TB by focusing on the recently approved drugsDrugApproved and the most promising candidatesCandidate that can contribute to current therapies. Antitubercular drug discovery: challengesen
dc.description.affiliationSão Paulo State University (UNESP) Institute of Chemistry
dc.description.affiliationUniversidad Nacional de Trujillo Escuela de Posgrado Unidad de Posgrado en Farmacia y Bioquímica
dc.description.affiliationSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara-Jaú Km 1, S/N, Campus Ville
dc.description.affiliationUnespSão Paulo State University (UNESP) Institute of Chemistry
dc.description.affiliationUnespSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara-Jaú Km 1, S/N, Campus Ville
dc.format.extent483-498
dc.identifierhttp://dx.doi.org/10.1007/978-3-031-15955-8_23
dc.identifier.citationIntegrated Science, v. 11, p. 483-498.
dc.identifier.dimensionspub.1156771591
dc.identifier.doi10.1007/978-3-031-15955-8_23
dc.identifier.isbn978-3-031-15954-1
dc.identifier.isbn978-3-031-15955-8
dc.identifier.issn2662-947X
dc.identifier.issn2662-9461
dc.identifier.orcid0000-0002-2460-2829
dc.identifier.orcid0000-0001-9797-639X
dc.identifier.orcid0000-0003-0187-4626
dc.identifier.scopus2-s2.0-85198871403
dc.identifier.urihttps://hdl.handle.net/11449/298445
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofIntegrated Science
dc.rights.accessRightsAcesso abertopt
dc.rights.sourceRightsoa_all
dc.rights.sourceRightsgreen
dc.sourceScopus
dc.sourceDimensions
dc.subjectAntitubercular drugs
dc.subjectDrug design
dc.subjectMycobacterium tuberculosis
dc.subjectNew drugs
dc.subjectTuberculosis
dc.titleThe Challenges of Antitubercular Drug Discoveryen
dc.typeCapítulo de livropt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublicationbc74a1ce-4c4c-4dad-8378-83962d76c4fd
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.campusUniversidade Estadual Paulista (UNESP), Instituto de Química, Araraquarapt

Arquivos